Bright Green to move forward with Alterola Biotech acquisition

Bright Green Corporation announced that it will move forward with its previously announced strategic arrangement and confirms its intention to exercise the call option on the total acquisition of the remaining issued and outstanding common stock of Alterola Biotech, a U.K.-based pharmaceutical company focused on developing cannabinoid and cannabinoid-like medicines and products. By exercising its option to purchase Alterola’s remaining issued and outstanding common stock over the coming months, Bright Green will complete the acquisition using Bright Green common stock.